Hepatitis wonder drug knocked back

The Pharmaceutical Benefits Advisory Committee has rejected a submission for the PBS listing of sofosbuvir (Sovaldi) for hepatitis C in patients with compensated liver disease.

Subsidising the direct-acting antiviral, which looks set to revolutionise the treatment of hepatitis C across the globe, would have an “unacceptably high financial impact on the health budget”, the Committee said.

And that impact is probably underestimated, due to an expected surge in the number of patients coming forward for a treatment that would be of shorter duration and far